Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study

Cancer Letters

Volumn 396, Issue , 2017, Pages 145-154

  Wang, Yi Jun ^a   Zhang, Yun Kai ^a   Zhang, Guan Nan ^a   Al Rihani, Sweilem B ^b   Wei, Meng Ning ^c   Gupta, Pranav ^a   Zhang, Xiao Yu ^a   Shukla, Suneet ^d   Ambudkar, Suresh V ^d   Kaddoumi, Amal ^b   Shi, Zhi ^c   Chen, Zhe Sheng ^a,c  

^a ST JOHN'S UNIVERSITY   (United States)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^c JINAN UNIVERSITY   (China)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABCB1 transporter; Combination chemotherapy; Multidrug resistance; Regorafenib; Tumor xenograft mouse model

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; REGORAFENIB; VINCRISTINE; ABCB1 PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INHIBITION; CELL COUNTING; CELLULAR DISTRIBUTION; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MTT ASSAY; MULTIDRUG RESISTANCE; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG INTERACTION; DRUG RESISTANCE; DRUG SCREENING; HEK293 CELL LINE; METABOLISM; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HEK293 CELLS; HUMANS; MICE; P-GLYCOPROTEINS; PACLITAXEL; PHENYLUREA COMPOUNDS; PYRIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85016410334     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2017.03.011     Document Type: Article

References (56)

1. [1] Shukla, S., Wu, C., Ambudkar, S.V., Development of inhibitors of ATP-binding cassette drug transporters–present status and challenges. Expert Opin. Drug Metab. Toxicol. 4 (2008), 205–223.
2. [2] Wu, C., Hsieh, C., Wu, Y., The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy. Mol. Pharm. 8 (2011), 1996–2011.
3. [3] Kathawala, R.J., Gupta, P., Ashby, C.R., Chen, Z., The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist. Updat. 18 (2015), 1–17.
4. [4] Holland, I.B., ABC transporters, mechanisms and biology: an overview. Essays Biochem. 50 (2011), 1–17.
5. [5] Assaraf, Y.G., Molecular basis of antifolate resistance. Cancer Metastasis Rev. 26 (2007), 153–181.
6. [6] Deeley, R.G., Westlake, C., Cole, S.P., Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 86 (2006), 849–899.
7. [7] Gottesman, M.M., Fojo, T., Bates, S.E., Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 (2002), 48–58.
8. [8] Sarkadi, B., Homolya, L., Szakacs, G., Varadi, A., Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev. 86 (2006), 1179–1236.
9. [9] Sodani, K., Patel, A., Kathawala, R.J., Chen, Z.S., Multidrug resistance associated proteins in multidrug resistance. Chin. J. Cancer 31 (2012), 58–72.
10. [10] Tiwari, A.K., Sodani, K., Dai, C., Ashby, C.R., Chen, Z., Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr. Pharm. Biotechnol. 12 (2011), 570–594.
11. [11] Sauna, Z.E., Smith, M.M., Müller, M., Kerr, K.M., Ambudkar, S.V., The mechanism of action of multidrug-resistance-linked P-glycoprotein. J. Bioenerg. Biomembr. 33 (2001), 481–491.
12. [12] Schinkel, A.H., Mayer, U., Wagenaar, E., Mol, C.A., van Deemter, L., Smit, J.J., et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 4028–4033.
13. [13] Alvarez, M., Paull, K., Monks, A., Hose, C., Lee, J.S., Weinstein, J., et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the national cancer institute anticancer drug screen. J. Clin. Invest. 95 (1995), 2205–2214.
14. [14] Schondorf, T., Kurbacher, C.M., Gohring, U.J., Benz, C., Becker, M., Sartorius, J., et al. Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines. Anticancer Res. 22 (2002), 2199–2203.
15. [15] Xu, X., Leo, C., Jang, Y., Chan, E., Padilla, D., Huang, B.C., et al. Dominant effector genetics in mammalian cells. Nat. Genet. 27 (2001), 23–29.
16. [16] Devine, S.E., Ling, V., Melera, P.W., Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance. Proc. Natl. Acad. Sci. U. S. A. 89 (1992), 4564–4568.
17. [17] Gros, P., Dhir, R., Croop, J., Talbot, F., A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 7289–7293.
18. [18] Mickley, L.A., Spengler, B.A., Knutsen, T.A., Biedler, J.L., Fojo, T., Gene rearrangement: a novel mechanism for MDR-1 gene activation. J. Clin. Invest. 99 (1997), 1947–1957.
19. [19] Leighton, J.C. Jr., Goldstein, L.J., P-glycoprotein in adult solid tumors. expression and prognostic significance. Hematol. Oncol. Clin. North Am. 9 (1995), 251–273.
20. [20] Pérez-Sayáns, M., Somoza-Martín, J.M., Barros-Angueira, F., Diz, P.G., Rey, J.M.G., García-García, A., Multidrug resistance in oral squamous cell carcinoma: the role of vacuolar ATPases. Cancer Lett. 295 (2010), 135–143.
21. [21] Marie, J.P., P-glycoprotein in adult hematologic malignancies. Hematol. Oncol. Clin. North Am. 9 (1995), 239–249.
22. [22] Verrelle, P., Meissonnier, F., Fonck, Y., Feillel, V., Dionet, C., Kwiatkowski, F., et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J. Natl. Cancer Inst. 83 (1991), 111–116.
23. ® in combination with paclitaxel in solid tumors. Oncologist, 2012 theoncologist. 2012-0080.
24. [24] Kunz, P.L., He, A.R., Colevas, A.D., Pishvaian, M.J., Hwang, J.J., Clemens, P.L., et al. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Invest. New Drugs 30 (2012), 2364–2370.
25. [25] O'Brien, M.M., Lacayo, N.J., Lum, B.L., Kshirsagar, S., Buck, S., Ravindranath, Y., et al. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the children's oncology group. Pediatr. Blood Cancer 54 (2010), 694–702.
26. [26] Zhang, H., Patel, A., Ma, S., Li, X.J., Zhang, Y., Yang, P., et al. In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1. Br. J. Pharmacol. 171 (2014), 5845–5857.
27. [27] Demetri, G.D., Reichardt, P., Kang, Y., Blay, J., Rutkowski, P., Gelderblom, H., et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (2013), 295–302.
28. [28] Grothey, A., Van Cutsem, E., Sobrero, A., Siena, S., Falcone, A., Ychou, M., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (2013), 303–312.
29. [29] Wilhelm, S.M., Dumas, J., Adnane, L., Lynch, M., Carter, C.A., Schütz, G., et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129 (2011), 245–255.
30. [30] Chen, D., Wei, L., Yu, J., Zhang, L., Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. Clin. Cancer Res. 20 (2014), 3472–3484.
31. [31] Wang, Y., Kathawala, R.J., Zhang, Y., Patel, A., Kumar, P., Shukla, S., et al. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochem. Pharmacol. 90 (2014), 367–378.
32. [32] Zhang, H., Kathawala, R.J., Wang, Y., Zhang, Y., Patel, A., Shukla, S., et al. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. Int. J. Biochem. Cell Biol. 51 (2014), 111–119.
33. [33] Zhang, Y., Zhang, Y., Wang, Y., Vispute, S.G., Jain, S., Chen, Y., et al. Esters of the marine-derived triterpene sipholenol A reverse P-GP-mediated drug resistance. Mar. Drugs 13 (2015), 2267–2286.
34. [34] Guo, H.Q., Zhang, G.N., Wang, Y.J., Zhang, Y.K., Sodani, K., Talele, T.T., et al. Beta-elemene, a compound derived from rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter. Oncol. Rep. 31 (2014), 858–866.
35. [35] Zhang, H., Wang, Y., Zhang, Y., Wang, D., Kathawala, R.J., Patel, A., et al. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Cancer Lett. 350 (2014), 61–68.
36. [36] Ambudkar, S.V., Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods Enzymol. 292 (1998), 504–514.
37. [37] Zhang, Y.K., Zhang, G.N., Wang, Y.J., Patel, B.A., Talele, T.T., Yang, D.H., et al. Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. Sci. Rep., 6, 2016, 25694.
38. [38] Zhang, Y.K., Zhang, H., Zhang, G.N., Wang, Y.J., Kathawala, R.J., Si, R., et al. Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents. Oncotarget 6 (2015), 24277–24290.
39. [39] Sherman, W., Day, T., Jacobson, M.P., Friesner, R.A., Farid, R., Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 49 (2006), 534–553.
40. [40] Wang, Y.J., Huang, Y., Anreddy, N., Zhang, G.N., Zhang, Y.K., Xie, M., et al. Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin. Oncotarget 7 (2016), 5877–5891.
41. [41] Wang, Y.J., Patel, B.A., Anreddy, N., Zhang, Y.K., Zhang, G.N., Alqahtani, S., et al. Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1. Sci. Rep., 7, 2017, 42106.
42. [42] Wang, D.S., Patel, A., Shukla, S., Zhang, Y.K., Wang, Y.J., Kathawala, R.J., et al. Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget 5 (2014), 4529–4542.
43. [43] Anreddy, N., Patel, A., Zhang, Y.K., Wang, Y.J., Shukla, S., Kathawala, R.J., et al. A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. Oncotarget 6 (2015), 39276–39291.
44. [44] Kathawala, R.J., Wei, L., Anreddy, N., Chen, K., Patel, A., Alqahtani, S., et al. The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. Oncotarget 6 (2015), 510–521.
45. [45] Calcagno, A.M., Ambudkar, S.V., Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells. Methods Mol. Biol. 596 (2010), 77–93.
46. [46] Missov, E., Calzolari, C., Pau, B., Circulating cardiac troponin I in severe congestive heart failure. Circulation 96 (1997), 2953–2958.
47. [47] Wang, T.J., Significance of circulating troponins in heart failure: if these walls could talk. Circulation 116 (2007), 1217–1220.
48. [48] Nemzek, J., Bolgos, G., Williams, B., Remick, D., Differences in normal values for murine white blood cell counts and other hematological parameters based on sampling site. Inflamm. Res. 50 (2001), 523–527.
49. [49] Chen, K.G., Sikic, B.I., Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin. Cancer Res. 18 (2012), 1863–1869.
50. [50] Baer, M.R., George, S.L., Dodge, R.K., O'Loughlin, K.L., Minderman, H., Caligiuri, M.A., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: cancer and leukemia group B study 9720. Blood 100 (2002), 1224–1232.
51. [51] He, K., Chen, D., Ruan, H., Li, X., Tong, J., Xu, X., et al. BRAFV600E-dependent mcl-1 stabilization leads to everolimus resistance in colon cancer cells. Oncotarget 7 (2016), 47699–47710.
52. [52] Bozic, I., Reiter, J.G., Allen, B., Antal, T., Chatterjee, K., Shah, P., et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife, 2, 2013, e00747.
53. [53] Diyabalanage, H.V., Granda, M.L., Hooker, J.M., Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett. 329 (2013), 1–8.
54. [54] Zhang, W., Li, Y., Wei, M., Chen, Y., Qiu, J., Jiang, Q., et al. Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer. Cancer Lett. 386 (2017), 100–109.
55. [55] Schmieder, R., Hoffmann, J., Becker, M., Bhargava, A., Müller, T., Kahmann, N., et al. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer. Int. J. Cancer 135 (2014), 1487–1496.
56. [56] Abou-Elkacem, L., Arns, S., Brix, G., Gremse, F., Zopf, D., Kiessling, F., et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol. Cancer. Ther. 12 (2013), 1322–1331.